<DOC>
	<DOCNO>NCT01148550</DOCNO>
	<brief_summary>The specific aim study ( 1 ) determine clinical phenotype natural history hepatic RC FAO disorder , ( 2 ) determine correlation genotype phenotype , ( 3 ) determine circulate biomarkers reflect diagnosis predict liver disease progression survival native liver , ( 4 ) determine clinical outcome disorder follow liver transplantation , ( 5 ) develop repository serum , plasma , urine , tissue DNA specimen use ancillary study . To accomplish aim , ChiLDREN investigator clinical site ( currently 15 site ) prospectively collect define data specimen uniform fashion fix interval relatively large number subject . Clinical information DNA sample collect subject parent enhance potential meaningful research disorder . A biobank subject specimens DNA sample establish use ancillary study perform addition study .</brief_summary>
	<brief_title>Longitudinal Study Mitochondrial Hepatopathies</brief_title>
	<detailed_description>This study conduct part NIH-supported Childhood Liver Disease Research Education Network ( ChiLDREN ) . ChiLDREN investigate rare cholestatic liver disease childhood : alpha-1 antitrypsin deficiency ( A1AT ) , Alagille 's Syndrome ( AGS ) , progressive familial intrahepatic cholestasis ( PFIC ) , bile acid synthesis defect mitochondrial hepatopathies ( previously study Cholestatic Liver Disease Consortium [ CLiC ] ) ; biliary atresia ( previously study Biliary Atresia Research Consortium [ BARC ] ) ; neonatal hepatitis ; cystic fibrosis liver disease , study new branch ChiLDREN know Cystic Fibrosis Liver Disease ( CFLD ) Network . In protocol , mitochondrial hepatopathies child young adult investigate . The focus respiratory chain defect ( RC ) defect fatty acid oxidation ( FAO ) . There little known full spectrum severity long-term natural history mitochondrial hepatopathies . Moreover , disorder subject prospective , rigorous clinicopathological scrutiny .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Mitochondrial Diseases</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Liver Failure , Acute</mesh_term>
	<criteria>Subjects Group 1 ( Mitochondrial Hepatopathy group ) must meet follow inclusion criterion : 1 . Children young adult suspect documented hepatic RC defector FAO defect birth 18 year old ( 18 year ) . 2 . Both gender , race ethnic group . 3 . Participants must meet one follow set criterion ( A B ) : A . Potential subject present acute chronic liver disease acute liver failure liver transplant must meet one Clinical Criteria 1 one Clinical Criteria 2 list : 1 . Clinical Criteria 1 ( one follow ) 1.Acute liver failure , define severe liver dysfunction either 1 ) INR &gt; 1.5 prothrombin time &gt; 15 second encephalopathy 2 ) INR &gt; 2.0 prothrombin time &gt; 20 second without encephalopathy ; occur within 8 week onset illness ; know underlie chronic liver disease , 2.Acute liver disease define elevate AST ALT &gt; 1.25 ULN CK &lt; 1000u/L conjugated bilirubin &gt; 2.0 mg/dl &gt; 20 % total bilirubin , 3.Chronic liver disease define : elevate ALT AST ( &gt; 1.25 ULN ) &gt; 6 month , conjugate hyperbilirubinemia ( conjugate [ direct ] &gt; 2.0 mg/dl &gt; 20 % total bilirubin ) &gt; 6 month clinical stigma chronic liver disease , include chronic hepatomegaly , clinical finding complication cirrhosis portal hypertension , impair liver synthetic function , intractable pruritus explainable liver disease endstage liver disease , abnormal liver histology include hepatic fibrosis cirrhosis , microvesicular steatosis , canalicular cholestasis , balloon granular red hepatocytes ( AKA onocytes ) , intralobular collapse/regeneration And 2 . Clinical Criteria 2 ( one following : 1.Prior history extrahepatic organ involvement accompany one sign symptoms associate mitochondrial dysfunction ( e.g . hypotonia , neurodevelopmental delay , seizure disorder require treatment valproic acid , nystagmus , cardiomyopathy , renal tubulopathy , bone marrow failure , myopathy , hear loss ) , 2.Lactic acidosis ( arterial blood freeflowing venous blood level &gt; 2.5 mmol/L &gt; 22.5 mg/dl age increase lactate : pyruvate ratio [ &gt; 25.0 ] ) 3.Hypoglycemia ( blood glucose &lt; 45 mg/dl measurement ) hypoketonuria ( &lt; 1+ urine ketone dipstick urine specimen obtain within 4 hour collect blood low glucose concentration ) , 4.Abnormal acyl carnitine profile , 5.Documented biochemical ( enzymatic ) genetic diagnosis 3b . Potential participant undergone liver transplantation acute liver failure end stage liver disease due suspect confirmed mitochondrial hepatopathy ; transplantation may perform nonChiLDREN medical center ChiLDREN Clinical Site . B . Potential subject already liver transplant must meet criterion 1 either criterion 2 criterion 3 : 1.Previous liver transplantation , AND 2.Suspected mitochondrial liver disease , base upon meet one follow criterion : Had prior history extrahepatic organ involvement accompany sign symptom associate mitochondrial dysfunction ( e.g. , hypotonia , neurodevelopmental delay , seizure disorder require treatment valproic acid , nystagmus , cardiomyopathy , renal tubulopathy , bone marrow failure , myopathy , hear loss ) , OR A prior history lactic acidosis ( arterial blood freeflowing venous blood level &gt; 2.5 mmol/L &gt; 22.5 mg/dl age increase lactate : pyruvate ratio [ &gt; 25.0 ] ) , OR A prior history hypoglycemia ( blood glucose &lt; 45 mg/dl measurement ) hypoketonuria ( â‰¤1+ urine ketone dipstick urine specimen obtain within 4 hour collect blood low glucose concentration ) , OR A prior history abnormal acyl carnitine profile , OR Documented biochemical ( enzymatic ) genetic diagnosis mitochondrial disorder 3.A document ( confirm ) mitochondrial disorder base upon confirmation criterion specify protocol . Subjects Group 2 ( Suspected Mitochondrial Hepatopathy meeting Group 1 enrollment criterion ) must meet follow inclusion criterion : 1 . Children young adult suspect hepatic RC defect FAO defect birth 18 year meet clinical inclusion criterion list acute chronic liver disease acute liver failure . 2 . Both gender , race ethnic group . Subjects either Group 1 2 must follow exclusion criterion : 1 . Inability comply longitudinal followup describe . 2 . Failure family/patient sign inform consent/assent document HIPAA authorization form . 3 . Known Medium Chain Acyl CoA Dehydrogenase deficiency ( MCAD ) . 4 . Other known cause liver disease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>neonatal acute liver failure</keyword>
	<keyword>late-onset liver failure</keyword>
	<keyword>cholestasis ,</keyword>
	<keyword>fatty liver ,</keyword>
	<keyword>liver dysfunction ,</keyword>
	<keyword>cirrhosis</keyword>
</DOC>